242 related articles for article (PubMed ID: 20340136)
21. Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants.
Greenblatt MS; Beaudet JG; Gump JR; Godin KS; Trombley L; Koh J; Bond JP
Oncogene; 2003 Feb; 22(8):1150-63. PubMed ID: 12606942
[TBL] [Abstract][Full Text] [Related]
22. INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck.
Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
Virchows Arch; 2002 Aug; 441(2):133-42. PubMed ID: 12189502
[TBL] [Abstract][Full Text] [Related]
23. The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements.
D'Amico M; Wu K; Fu M; Rao M; Albanese C; Russell RG; Lian H; Bregman D; White MA; Pestell RG
Cancer Res; 2004 Jun; 64(12):4122-30. PubMed ID: 15205322
[TBL] [Abstract][Full Text] [Related]
24. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
[TBL] [Abstract][Full Text] [Related]
25. Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma.
Peng CY; Chen TC; Hung SP; Chen MF; Yeh CT; Tsai SL; Chu CM; Liaw YF
Anticancer Res; 2002; 22(2B):1265-71. PubMed ID: 12168936
[TBL] [Abstract][Full Text] [Related]
26. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice.
Krimpenfort P; Quon KC; Mooi WJ; Loonstra A; Berns A
Nature; 2001 Sep; 413(6851):83-6. PubMed ID: 11544530
[TBL] [Abstract][Full Text] [Related]
27. A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families.
Yakobson E; Eisenberg S; Isacson R; Halle D; Levy-Lahad E; Catane R; Safro M; Sobolev V; Huot T; Peters G; Ruiz A; Malvehy J; Puig S; Chompret A; Avril MF; Shafir R; Peretz H; Bressac-de Paillerets B
Eur J Hum Genet; 2003 Apr; 11(4):288-96. PubMed ID: 12700603
[TBL] [Abstract][Full Text] [Related]
28. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations.
Lal G; Liu L; Hogg D; Lassam NJ; Redston MS; Gallinger S
Genes Chromosomes Cancer; 2000 Apr; 27(4):358-61. PubMed ID: 10719365
[TBL] [Abstract][Full Text] [Related]
29. p16(INK4a) Peptide mimetics identified via virtual screening.
Klein MA; Mayo KH; Kratzke RA
Bioorg Med Chem Lett; 2010 Jan; 20(1):403-5. PubMed ID: 19914831
[TBL] [Abstract][Full Text] [Related]
30. Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma.
Soufir N; Lacapere JJ; Bertrand G; Matichard E; Meziani R; Mirebeau D; Descamps V; Gérard B; Archimbaud A; Ollivaud L; Bouscarat F; Baccard M; Lanternier G; Saïag P; Lebbé C; Basset-Seguin N; Crickx B; Cave H; Grandchamp B
Br J Cancer; 2004 Jan; 90(2):503-9. PubMed ID: 14735200
[TBL] [Abstract][Full Text] [Related]
31. Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia.
Kresty LA; Mallery SR; Knobloch TJ; Song H; Lloyd M; Casto BC; Weghorst CM
Cancer Res; 2002 Sep; 62(18):5295-300. PubMed ID: 12234999
[TBL] [Abstract][Full Text] [Related]
32. Alterations of the INK4a-ARF gene locus in pleomorphic adenoma of the parotid gland.
Weber A; Langhanki L; Schütz A; Wittekind C; Bootz F; Tannapfel A
J Pathol; 2002 Nov; 198(3):326-34. PubMed ID: 12375265
[TBL] [Abstract][Full Text] [Related]
33. Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information.
Ruas M; Brookes S; McDonald NQ; Peters G
Oncogene; 1999 Sep; 18(39):5423-34. PubMed ID: 10498896
[TBL] [Abstract][Full Text] [Related]
34. Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF.
Rizos H; Darmanian AP; Holland EA; Mann GJ; Kefford RF
J Biol Chem; 2001 Nov; 276(44):41424-34. PubMed ID: 11518711
[TBL] [Abstract][Full Text] [Related]
35. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds.
Flores JF; Pollock PM; Walker GJ; Glendening JM; Lin AH; Palmer JM; Walters MK; Hayward NK; Fountain JW
Oncogene; 1997 Dec; 15(24):2999-3005. PubMed ID: 9416844
[TBL] [Abstract][Full Text] [Related]
36. Phenotype-rescue of cyclin-dependent kinase inhibitor p16/INK4A defects in a spontaneous canine cell model of breast cancer.
DeInnocentes P; Agarwal P; Bird RC
J Cell Biochem; 2009 Feb; 106(3):491-505. PubMed ID: 19130492
[TBL] [Abstract][Full Text] [Related]
37. p16 proteins from melanoma-prone families are deficient in binding to Cdk4.
Reymond A; Brent R
Oncogene; 1995 Sep; 11(6):1173-8. PubMed ID: 7566978
[TBL] [Abstract][Full Text] [Related]
38. Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein.
Ceha HM; Nasser I; Medema RH; Slebos RJ
Biochem Biophys Res Commun; 1998 Aug; 249(2):550-5. PubMed ID: 9712735
[TBL] [Abstract][Full Text] [Related]
39. Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.
Ming Z; Lim SY; Rizos H
Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33076392
[TBL] [Abstract][Full Text] [Related]
40. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene.
Tsao H; Benoit E; Sober AJ; Thiele C; Haluska FG
Cancer Res; 1998 Jan; 58(1):109-13. PubMed ID: 9426066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
